Early antibiotic use and incidence of necrotising enterocolitis in very preterm infants: A protocol for a UK based observational study using routinely recorded data

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Early antibiotic use and incidence of necrotising enterocolitis in very preterm infants : A protocol for a UK based observational study using routinely recorded data. / Shen, Rene; Embleton, Nicholas; Lyng Forman, Julie; Gale, Chris; Griesen, Gorm; Sangild, Per Torp; Uthaya, Sabita; Berrington, Janet.

I: BMJ Open, Bind 12, Nr. 11, e065934, 2022.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Shen, R, Embleton, N, Lyng Forman, J, Gale, C, Griesen, G, Sangild, PT, Uthaya, S & Berrington, J 2022, 'Early antibiotic use and incidence of necrotising enterocolitis in very preterm infants: A protocol for a UK based observational study using routinely recorded data', BMJ Open, bind 12, nr. 11, e065934. https://doi.org/10.1136/bmjopen-2022-065934

APA

Shen, R., Embleton, N., Lyng Forman, J., Gale, C., Griesen, G., Sangild, P. T., Uthaya, S., & Berrington, J. (2022). Early antibiotic use and incidence of necrotising enterocolitis in very preterm infants: A protocol for a UK based observational study using routinely recorded data. BMJ Open, 12(11), [e065934]. https://doi.org/10.1136/bmjopen-2022-065934

Vancouver

Shen R, Embleton N, Lyng Forman J, Gale C, Griesen G, Sangild PT o.a. Early antibiotic use and incidence of necrotising enterocolitis in very preterm infants: A protocol for a UK based observational study using routinely recorded data. BMJ Open. 2022;12(11). e065934. https://doi.org/10.1136/bmjopen-2022-065934

Author

Shen, Rene ; Embleton, Nicholas ; Lyng Forman, Julie ; Gale, Chris ; Griesen, Gorm ; Sangild, Per Torp ; Uthaya, Sabita ; Berrington, Janet. / Early antibiotic use and incidence of necrotising enterocolitis in very preterm infants : A protocol for a UK based observational study using routinely recorded data. I: BMJ Open. 2022 ; Bind 12, Nr. 11.

Bibtex

@article{06ca966c4cf7475d8bcbe46425894074,
title = "Early antibiotic use and incidence of necrotising enterocolitis in very preterm infants: A protocol for a UK based observational study using routinely recorded data",
abstract = "Introduction Necrotising enterocolitis (NEC) remains a major contributor to preterm mortality and morbidity. Prolonged duration of antibiotic therapy after delivery is associated with later NEC development but recent evidence suggests that absence of antibiotic treatment after delivery may also increase NEC risk. We will explore this controversy using a large pre-existing dataset of preterm infants in the UK. Methods and analysis This is a retrospective cohort study using data from UK National Neonatal Research Database (NNRD) for infants born 1 January 2012 to 31 December 2020. Eligible infants will be <32 weeks gestation, alive on day 3. Primary outcome is development of severe NEC, compared in infants receiving early antibiotics (days 1-2 after birth) and those not. Subgroup analysis on duration of early antibiotic exposure will also occur. Secondary outcomes are: late onset sepsis, total antibiotic use, predischarge mortality, retinopathy of prematurity, intraventricular haemorrhage, bronchopulmonary dysplasia, focal intestinal perforation and any abdominal surgery. To address competing risks, incidence of death before day 7, 14 and 28 will be analysed. We will perform logistic regression and propensity score matched analyses. Statistical analyses will be guided by NEC risk factors, exposures and outcome presented in a causal diagram. These covariates include but are not limited to gestational age, birth weight, small for gestational age, sex, ethnicity, delivery mode, delivery without labour, Apgar score, early feeding and probiotic use. Sensitivity analyses of alternate NEC definitions, specific antibiotics and time of initiation will occur. Ethics and dissemination We will use deidentified data from NNRD, which holds permissions for the original data, from which parents can opt out and seek study-specific research ethics approval. The results will help to determine optimal use of early antibiotics for very preterm infants. Implications This data will help optimise early antibiotic use in preterm infants. Trial registration number ISRCTN55101779. ",
keywords = "bacteriology, neonatal intensive & critical care, paediatric gastroenterology",
author = "Rene Shen and Nicholas Embleton and {Lyng Forman}, Julie and Chris Gale and Gorm Griesen and Sangild, {Per Torp} and Sabita Uthaya and Janet Berrington",
note = "Publisher Copyright: {\textcopyright} Author(s) (or their employer(s)) 2022.",
year = "2022",
doi = "10.1136/bmjopen-2022-065934",
language = "English",
volume = "12",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "11",

}

RIS

TY - JOUR

T1 - Early antibiotic use and incidence of necrotising enterocolitis in very preterm infants

T2 - A protocol for a UK based observational study using routinely recorded data

AU - Shen, Rene

AU - Embleton, Nicholas

AU - Lyng Forman, Julie

AU - Gale, Chris

AU - Griesen, Gorm

AU - Sangild, Per Torp

AU - Uthaya, Sabita

AU - Berrington, Janet

N1 - Publisher Copyright: © Author(s) (or their employer(s)) 2022.

PY - 2022

Y1 - 2022

N2 - Introduction Necrotising enterocolitis (NEC) remains a major contributor to preterm mortality and morbidity. Prolonged duration of antibiotic therapy after delivery is associated with later NEC development but recent evidence suggests that absence of antibiotic treatment after delivery may also increase NEC risk. We will explore this controversy using a large pre-existing dataset of preterm infants in the UK. Methods and analysis This is a retrospective cohort study using data from UK National Neonatal Research Database (NNRD) for infants born 1 January 2012 to 31 December 2020. Eligible infants will be <32 weeks gestation, alive on day 3. Primary outcome is development of severe NEC, compared in infants receiving early antibiotics (days 1-2 after birth) and those not. Subgroup analysis on duration of early antibiotic exposure will also occur. Secondary outcomes are: late onset sepsis, total antibiotic use, predischarge mortality, retinopathy of prematurity, intraventricular haemorrhage, bronchopulmonary dysplasia, focal intestinal perforation and any abdominal surgery. To address competing risks, incidence of death before day 7, 14 and 28 will be analysed. We will perform logistic regression and propensity score matched analyses. Statistical analyses will be guided by NEC risk factors, exposures and outcome presented in a causal diagram. These covariates include but are not limited to gestational age, birth weight, small for gestational age, sex, ethnicity, delivery mode, delivery without labour, Apgar score, early feeding and probiotic use. Sensitivity analyses of alternate NEC definitions, specific antibiotics and time of initiation will occur. Ethics and dissemination We will use deidentified data from NNRD, which holds permissions for the original data, from which parents can opt out and seek study-specific research ethics approval. The results will help to determine optimal use of early antibiotics for very preterm infants. Implications This data will help optimise early antibiotic use in preterm infants. Trial registration number ISRCTN55101779.

AB - Introduction Necrotising enterocolitis (NEC) remains a major contributor to preterm mortality and morbidity. Prolonged duration of antibiotic therapy after delivery is associated with later NEC development but recent evidence suggests that absence of antibiotic treatment after delivery may also increase NEC risk. We will explore this controversy using a large pre-existing dataset of preterm infants in the UK. Methods and analysis This is a retrospective cohort study using data from UK National Neonatal Research Database (NNRD) for infants born 1 January 2012 to 31 December 2020. Eligible infants will be <32 weeks gestation, alive on day 3. Primary outcome is development of severe NEC, compared in infants receiving early antibiotics (days 1-2 after birth) and those not. Subgroup analysis on duration of early antibiotic exposure will also occur. Secondary outcomes are: late onset sepsis, total antibiotic use, predischarge mortality, retinopathy of prematurity, intraventricular haemorrhage, bronchopulmonary dysplasia, focal intestinal perforation and any abdominal surgery. To address competing risks, incidence of death before day 7, 14 and 28 will be analysed. We will perform logistic regression and propensity score matched analyses. Statistical analyses will be guided by NEC risk factors, exposures and outcome presented in a causal diagram. These covariates include but are not limited to gestational age, birth weight, small for gestational age, sex, ethnicity, delivery mode, delivery without labour, Apgar score, early feeding and probiotic use. Sensitivity analyses of alternate NEC definitions, specific antibiotics and time of initiation will occur. Ethics and dissemination We will use deidentified data from NNRD, which holds permissions for the original data, from which parents can opt out and seek study-specific research ethics approval. The results will help to determine optimal use of early antibiotics for very preterm infants. Implications This data will help optimise early antibiotic use in preterm infants. Trial registration number ISRCTN55101779.

KW - bacteriology

KW - neonatal intensive & critical care

KW - paediatric gastroenterology

U2 - 10.1136/bmjopen-2022-065934

DO - 10.1136/bmjopen-2022-065934

M3 - Journal article

C2 - 36379645

AN - SCOPUS:85141972895

VL - 12

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 11

M1 - e065934

ER -

ID: 330935243